Protalix BioTherapeutics, Inc. PLX

PLX Company Overview

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of recombinant therapeutic proteins produced through its proprietary plant cell–based protein expression platform, known as ProCellEx. The company operates within the biotechnology and rare disease sectors, with a strategic emphasis on treatments for lysosomal storage disorders, immunology-related conditions, and other specialty indications. Its core revenue drivers include product sales, licensing arrangements, supply agreements, and collaboration-related payments tied to commercialized and pipeline therapies.

The company is best known for developing taliglucerase alfa, marketed as Elelyso for Gaucher disease, which became the first FDA-approved plant cell–expressed recombinant therapeutic protein. Protalix has evolved from an early-stage platform biotechnology company into a commercial-stage organization with both marketed products and clinical-stage candidates. Its positioning is differentiated by its plant cell–based manufacturing system, which management states may offer advantages in scalability, production flexibility, and potentially lower manufacturing costs compared with traditional mammalian cell systems.